| Dr Devereaux Lashonti Nollie, MD | |
|
3533 S Alameda St, Corpus Christi, TX 78411-1721 | |
| (361) 694-4700 | |
| (361) 694-4701 |
| Full Name | Dr Devereaux Lashonti Nollie |
|---|---|
| Gender | Female |
| Speciality | Psychiatry & Neurology - Child & Adolescent Psychiatry |
| Location | 3533 S Alameda St, Corpus Christi, Texas |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1194865121 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | M3048 (Texas) | Secondary |
| 2084P0804X | Psychiatry & Neurology - Child & Adolescent Psychiatry | M3048 (Texas) | Primary |
| Entity Name | Children's Physician Services Of South Texas |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568658227 PECOS PAC ID: 3678478872 Enrollment ID: O20040324001704 |
News Archive
Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that preclinical results presented at the AACR-IASLC (American Academy of Cancer Research – International Association for the Study of Lung Cancer) Joint Conference based on work done at Synta and at the Dana-Farber Cancer Institute in Boston showed that STA-9090, a potent, synthetic inhibitor of heat shock protein 90 (Hsp90), demonstrated potent activity against 100% of all non-small cell lung cancer cell lines tested, including those with EGFR, HER2 or KRAS mutations including the EGFR T790 mutation that is present in roughly 50% of cases of erlotinib or gefitinib resistance.
Researchers at UT Southwestern Medical Center have found that a protein often located on the surface of fat droplets within cells - and especially abundant in the muscles of endurance athletes - can kick-start the more efficient and healthful breakdown of fat.
The study, published in Health Affairs, pointed the finger at the lack of health insurance - as well as conditions such as hypertension and medical errors - in the U.S. as part of the problem.
A phase II study led by researchers from The University of Texas MD Anderson Cancer Center found that treatment with atezolizumab and bevacizumab was well-tolerated and resulted in a 40% objective response rate in patients with advanced malignant peritoneal mesothelioma, a rare cancer in the lining of the abdomen.
Physicians at The Medical College of Wisconsin are conducting the KAST clinical trial at Froedtert Hospital to assess the safety and effectiveness of a new vertebral augmentation treatment (Kiva) for painful vertebral compression fractures (VCFs) due to osteoporosis.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Devereaux Lashonti Nollie, MD 3533 S Alameda St, Corpus Christi, TX 78411-1721 Ph: (361) 694-4700 | Dr Devereaux Lashonti Nollie, MD 3533 S Alameda St, Corpus Christi, TX 78411-1721 Ph: (361) 694-4700 |
News Archive
Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that preclinical results presented at the AACR-IASLC (American Academy of Cancer Research – International Association for the Study of Lung Cancer) Joint Conference based on work done at Synta and at the Dana-Farber Cancer Institute in Boston showed that STA-9090, a potent, synthetic inhibitor of heat shock protein 90 (Hsp90), demonstrated potent activity against 100% of all non-small cell lung cancer cell lines tested, including those with EGFR, HER2 or KRAS mutations including the EGFR T790 mutation that is present in roughly 50% of cases of erlotinib or gefitinib resistance.
Researchers at UT Southwestern Medical Center have found that a protein often located on the surface of fat droplets within cells - and especially abundant in the muscles of endurance athletes - can kick-start the more efficient and healthful breakdown of fat.
The study, published in Health Affairs, pointed the finger at the lack of health insurance - as well as conditions such as hypertension and medical errors - in the U.S. as part of the problem.
A phase II study led by researchers from The University of Texas MD Anderson Cancer Center found that treatment with atezolizumab and bevacizumab was well-tolerated and resulted in a 40% objective response rate in patients with advanced malignant peritoneal mesothelioma, a rare cancer in the lining of the abdomen.
Physicians at The Medical College of Wisconsin are conducting the KAST clinical trial at Froedtert Hospital to assess the safety and effectiveness of a new vertebral augmentation treatment (Kiva) for painful vertebral compression fractures (VCFs) due to osteoporosis.
› Verified 6 days ago
Umamaheswara Rao Maruvada, MD Psychiatry & Neurology Medicare: May Accept Medicare Assignments Practice Location: 4234 Weber Road, Corpus Christi, TX 78411 Phone: 361-857-2090 Fax: 361-814-6302 | |
Marcos J. Valdez, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 3533 S Alameda St, Corpus Christi, TX 78411 Phone: 361-694-6747 Fax: 361-808-2070 | |
Dr. Chad Bradford, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 10651 E St, Corpus Christi, TX 78419 Phone: 361-961-3620 | |
Dr. Nestor Hugo Praderio, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1315 Santa Fe St Ste 201, Corpus Christi, TX 78404 Phone: 361-887-9600 Fax: 361-883-1661 | |
John Marcus Kirk, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 205 S Enterprize Pkwy, Corpus Christi, TX 78405 Phone: 361-939-6510 | |
Dr. Lisa Marie Vela, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1533 S Brownlee Blvd, Corpus Christi, TX 78404 Phone: 361-886-3065 Fax: 361-886-3093 |